DIPG

  •   Erika Vial Monteverdi

    Press release from Oncoceutics curated by Executive Director Erika Vial Monteverdi.

    The U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to the drug ONC201 for treating a type of brain tumor known as “H3 K27M-mutant glioma,” which is primarily found in children. Alongside the Musella Foundation For Brain Tumor Research & Information, Inc, and the company xCures, Cancer Commons has been supporting this program to help patients in need.

    Go to full article published by Novocure on Business Wire.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •  

    Facilitating Access to Treatment for Children with Brain Cancer

    With: Leslie Jared, RN, MSN

    A Q&A with Leslie Jared, RN, MSN, Nurse Navigator at Cancer Commons. Email: leslie.jared@cancercommons.org Q: A midline glioma is a type of brain tumor that is particularly dangerous because of its nature and its location in the brain. It often… Read more »

  •   George Lundberg, MD

    Article from EurekAlert curated by Editor in Chief George Lundberg, MD, who notes: 

    Researchers have shown that a combination therapy is effective against cancer cells in test-tube experiments and laboratory animals. It has not yet been tested in humans.

    Go to full article published by EurekAlert.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from ScienceDaily curated by Editor in Chief George Lundberg, MD, who notes: 

    A genetic mutation known as PPN1D has been found to be a possible point of attack for research into the childhood cancer diffuse intrinsic pontine glioma (DIPG).

    Go to full article published by ScienceDaily.

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    DIPG is a rare, malignant brain tumor. Three hundred Americans, usually children, are diagnosed with DIPG each year. Its location (pons), its sublocation (intrinsic), its growth character (diffuse), and its cell type (glioma) describe a very difficult cancer to treat. Here is how one prestigious cancer center (Dana-Farber Cancer Institute) explains DIPG.

    .

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD:

    A brainstem glioma is a very serious disease that is rare and mostly affects children. Diffuse pontine intrinsic glioma  (DPIG) is one type of brainstem glioma. For an authoritative, up-to-date, detailed, comprehensive, and unbiased overview of brainstem gliomas, check out this presentation and discussion. (You may be required to register for free to view it.)

     

  •  

    Case Report in the Journal of Neurosurgery Highlights Potential of ONC201 in H3 K27M-mutant DIPG

    Last fall, we announced our collaboration with Musella Foundation, xCures, The Cure Starts Now Foundation, Michael Mosier Defeat DIPG Foundation, and Oncoceutics to help patients access ONC201, a new, experimental treatment for a type of brain tumor known as diffuse intrinsic pontine glioma (DIPG), as well as other gliomas… Read more »

  •  

    xCures to Implement an Intermediate Size Expanded Access Protocol for ONC201 in H3 K27M-mutant Gliomas

    LOS ALTOS, Calif., March 12, 2019 /PRNewswire/ — xCures and Cancer Commons are pleased to announce a collaboration with Oncoceutics to implement an Expanded Access program for ONC201. Part of this Expanded Access program is an intermediate size Expanded Access protocol for… Read more »

  •  

    Promising Developments for Brain Tumor Drug ONC201

    In September, we announced our collaboration with Musella Foundation, xCures, and Oncoceutics to help patients access ONC201, a potential new treatment for a type of brain tumor known as diffuse intrinsic pontine glioma (DIPG), as well as other gliomas with a genetic mutation known as H3… Read more »

  •  

    Patient Foundation Collaboration to Advance ONC201 in DIPG and other H3 K27M-mutant Gliomas

    Musella Foundation, Cancer Commons, xCures and Oncoceutics announced the initiation of a collaboration to develop ONC201 as a new treatment for diffuse intrinsic pontine glioma (DIPG) and other H3 K27M-mutant gliomas. Critical to the collaboration is $1M in funding from… Read more »